CA Patent

CA2873075A1 — Nampt inhibitors

Assigned to AbbVie Inc · Expires 2013-07-14 · 13y expired

What this patent protects

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

USPTO Abstract

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

Drugs covered by this patent

mobocertinib-succinate (MOBOCERTINIB SUCCINATE)

Patent Metadata

Patent number: CA2873075A1
Jurisdiction: CA
Classification: —
Expires: 2013-07-14
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.